biostudies-literatureCacciaglia REuropean Research CouncilNIA NIH HHSfcae451https://www.ebi.ac.uk/biostudies/studies/S-EPMC11668178biostudies-literatureUnknown7(1)CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and in cognitively unimpaired individuals. The CSF p-tau/Aβ42 ratio, a biomarker combining information from both pathophysiological processes, has emerged as a promising tool for monitoring disease progression, even at pre-clinical stages. Here, we studied the association between the CSF p-tau/Aβ42 ratio with downstream markers of pre-clinical Alzheimer's disease progression including brain structure, glucose metabolism, fibrillary Aβ deposition and cognitive performance in 234 cognitively unimpaired individuals, who underwent cognitive testing, a lumbar puncture, MRI, 18F-fluBrain communicationsThe CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease.PMC11668178948677R01 AG068398Canas ASuarez-Calvet MGil CMGamez LIRadoi IARodriguez GHHuguet JSoteras AZetterberg HStankeviciute LSGrau-Rivera OGispert JDFalcon CFauria KHernandez LAlvarez PMSerra PGEscalante AGBallester APSerrat ABMolinuevo JLPascual MCacciaglia RPenas LHShekari MIglesias RDAguilar RAPradas SNinou JHEmilio MMartinez ACQuevenco FCGorriti ABPalacios ECumplido IBlennow KJaramillo MVMendez SPMahnaz MSFuentes SSanchez-Benavides GSanchez Benavides GAMilan MDKarine MEFGispert LCALFA StudyFreixedes LRRivera OGPolo ACalvet MSMinguillon CDiaz TMMenchon TPrat ASMarne PSalvado GVilanova MDeulofeu CHuesa GMila-Aloma MKnezevic IGomez CDVila ASFernandez BRTejedor NVJulian SFBeteta ADominguez RHarster LSfalseThe CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease.CSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features both in patients and in cognitively unimpaired individuals. The CSF p-tau/Aβ42 ratio, a biomarker combining information from both pathophysiological processes, has emerged as a promising tool for monitoring disease progression, even at pre-clinical stages. Here, we studied the association between the CSF p-tau/Aβ42 ratio with downstream markers of pre-clinical Alzheimer's disease progression including brain structure, glucose metabolism, fibrillary Aβ deposition and cognitive performance in 234 cognitively unimpaired individuals, who underwent cognitive testing, a lumbar puncture, MRI, 18F-flu2025-01-01T00:00:00Z20252026-06-03T04:57:11.285Z2025-04-05T09:28:30.343ZS-EPMC116681783972310610.1093/braincomms/fcae451